Table 1.
Clinical characteristics of control and HCV+ study groups.
| Parameter | Chronic HCV (F4a) |
Chronic HCV (F0-1a) |
Uninfected controls |
|---|---|---|---|
| Number of participants | 7 | 11 | 9 |
| Sex | 6 (M), 1 (F) | 7 (M), 4 (F) | 4 (M), 5 (F) |
| Mean age years ± SD (range) | 59.9 ± 11.7 (45–76) | 57.3 ± 7.8 (41–64) | 43.6 ± 10.0 (25–54) |
| Race | Caucasian (6), East Indian (1) |
Caucasian (10), First Nations (1) |
Caucasian (9) |
| Mean baseline fibrosis score (kPab) ±SD (24 weeks post-SVRc) | 22.5 ± 14.94 (10.5 ± 2.6, n = 4) | 5.4 ±1.7 (5.9 ±1.8, n = 4) | n/a |
| IgG anti-CMVd | 3/4 seropositive | 4/4 seropositive | n/a |
a
Liver fibrosis score (Metavir fibrosis/cirrhosis F4, ≥12.5 kPa); (Metavir minimal fibrosis F0-1, ≤7.0 kPa).
b
kPa, KiloPascal (determined by transient elastography).
c
SVR, sustained virological response (undetectable HCV RNA 12 weeks after treatment cessation).
d
CMV, cytomegalovirus, assessed in subjects treated with DAA therapy. n/a, Not assessed. SD, standard deviation.